newsfilter
← Latest News
Business Wire·

Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib

—Oxford Finance Debt Facility for up to $125 Million— —Series B Warrants Will Expire in 75 Days, and if Fully Exercised, Could Provide An Additional $33.3 Million— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company